Cover Image
市場調查報告書

基質金屬蛋白酶 9 (明膠酶 B/92kDa-4型膠原酵素/92 kDa 明膠酶/MMP9/EC 3.4.24.35) :開發平台分析

Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 363574
出版日期 內容資訊 英文 55 Pages
訂單完成後即時交付
價格
Back to Top
基質金屬蛋白酶 9 (明膠酶 B/92kDa-4型膠原酵素/92 kDa 明膠酶/MMP9/EC 3.4.24.35) :開發平台分析 Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Pipeline Review, H2 2017
出版日期: 2017年09月30日 內容資訊: 英文 55 Pages
簡介

基質金屬蛋白酶 9 (MMP-9) 是屬於鋅金屬蛋白酶家族的一員,在細胞外基質的局部的蛋白質分解,白血球移動及骨製骨破壞性融噬發揮重要作用。與彈性蛋白酶一起的MMP9,是底膜中的好中性移動的調整要素。MMP9,在創傷修復,血管新生及新血管新生擔任重要的工作。

本報告提供的基質金屬蛋白酶 9 (明膠酶 B/92kDa-4型膠原酵素/92 kDa 明膠酶/MMP9/EC 3.4.24.35的)抑制劑開發平台的現狀及最新更新的各開發階段比較分析,企業和研究機關開發中的治療藥,治療藥的評估,後期階段及中止的計劃相關資訊等最新的新聞和發表。

簡介

  • 調查範圍

基質金屬蛋白酶 9 (明膠酶 B/92kDa-4型膠原酵素/92 kDa 明膠酶/MMP9/EC 3.4.24.35) :概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/研究機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Calypso Biotech SA
  • Gilead Sciences, Inc.
  • Shulov Innovative Science Ltd.

藥物簡介

開發中止的產品

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1036TDB

Summary

According to the recently published report 'Matrix Metalloproteinase 9 - Pipeline Review, H2 2017'; Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) pipeline Target constitutes close to 18 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes.

Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Matrix metallopeptidase 9 (MMP-9) is a matrixin that belong to the zinc-metalloproteinases family. It plays an essential role in local proteolysis of the extracellular matrix and in leukocyte migration and bone osteoclastic resorption. MMP9 along with elastase, appears to be a regulatory factor in neutrophil migration across the basement membrane. MMP9 may play an important role in wound repair, angiogenesis and neovascularization.

The report 'Matrix Metalloproteinase 9 - Pipeline Review, H2 2017' outlays comprehensive information on the Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 7 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 6 molecules, respectively. Report covers products from therapy areas Central Nervous System, Oncology, Cardiovascular, Gastrointestinal, Dermatology, Genetic Disorders, Immunology, Musculoskeletal Disorders, Respiratory, Infectious Disease, Male Health, Ophthalmology and Undisclosed which include indications Myocardial Infarction, Neuropathic Pain, Congestive Heart Failure (Heart Failure), Crohn's Disease (Regional Enteritis), Hypertension, Marfan Syndrome, Wounds, Acute Pain, Adenocarcinoma Of The Gastroesophageal Junction, Aneurysm, Cancer Pain, Chronic Obstructive Pulmonary Disease (COPD), Chronic Pain, Cystic Fibrosis, Dupuytren Contracture, Epilepsy, Fibrosis, Gastric Cancer, Herpes Labialis (Oral Herpes), Keratoconjunctivitis sicca (Dry Eye), Liver Fibrosis, Lung Adenocarcinoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Cancer, Metastatic Colorectal Cancer, Metastatic Melanoma, Opium (Opioid) Addiction, Osteoarthritis Pain, Pancreatic Islet Transplant Rejection, Peyronies Disease, Pulmonary Fibrosis, Rheumatoid Arthritis, Solid Tumor, Squamous Non-Small Cell Lung Carcinoma, Stroke, Traumatic Brain Injury and Unspecified.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35)
  • The report reviews Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Overview
    • Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Companies Involved in Therapeutics Development
    • EA Pharma Co Ltd
    • Gilead Sciences Inc
    • Iproteos SL
    • Shulov Innovative Science Ltd
  • Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Drug Profiles
    • andecaliximab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AQU-005 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AQU-010 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AQU-118 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CALY-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IPRO-003 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Inhibit MMP-2 and MMP-9 for Crohn's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ND-336 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ND-478 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Protearin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant MMP-9 Replacement for Liver Fibrosis, Pulmonary Fibrosis, Peyronies Disease, Dupuytren Contracture and Pancreatic Islet Transplant Rejection - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Target MMP-9 for Wounds - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SI-1004 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SI-1005 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Matrix Metalloproteinase 9 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Carbonic Anhydrases and MMPs for Metastatic Melanoma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit MMP for Myocardial Infarction - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ZEP-3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Dormant Products
  • Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Discontinued Products
  • Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Product Development Milestones
    • Featured News & Press Releases
      • Nov 02, 2016: Abzena Provides Update on GS-5745
      • Sep 21, 2016: Gilead Terminates Phase 2/3 Study of GS-5745 in Patients With Ulcerative Colitis
      • Jun 28, 2016: NeuroMax Announces Start Phase 1 Clinical Trial of AQU-005 for the Treatment of Neuropathic Pain
      • May 13, 2015: Abzena provides an update on the clinical development of one of the humanized antibodies created using its Composite Human Antibody technology
      • Dec 26, 2011: New Antibodies Treat Autoimmune Disease in Mice
      • Oct 08, 2011: Researchers from Notre Dame university create breakthrough in neurological diseases
      • Oct 06, 2011: Notre Dame researchers make neurological disease breakthrough
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indications, H2 2017
  • Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Number of Products under Investigation by Universities/Institutes, H2 2017
  • Products under Investigation by Universities/Institutes, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by EA Pharma Co Ltd, H2 2017
  • Pipeline by Gilead Sciences Inc, H2 2017
  • Pipeline by Iproteos SL, H2 2017
  • Pipeline by Shulov Innovative Science Ltd, H2 2017
  • Dormant Products, H2 2017
  • Dormant Products, H2 2017 (Contd..1), H2 2017
  • Dormant Products, H2 2017 (Contd..2), H2 2017
  • Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Top 10 Indications, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top